Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or future financial performance, and use words such as“may,”“estimate,”“could,”“expect”,“look forward”,“believe”,“hope” and others. They are based on management's current expectations and are subject to factors and uncertainties that could cause actual results to differ materially from those described in the statements. These statements include those regarding the hope that Galectin's development program for belapectin will lead to the first therapy for the treatment of MASH, formerly known as NASH, with cirrhosis and those regarding the hope that our lead compounds will be successful in cancer immunotherapy and in other therapeutic indications. Factors that could cause actual performance to differ materially from those discussed in the forward-looking statements include, among others, full analysis of the NAVIGATE trial data may not produce positive data; Galectin may not be successful in developing effective treatments and/or obtaining the requisite approvals for the use of belapectin or any of its other drugs in development; the Company may not be successful in scaling up manufacturing and meeting requirements related to chemistry, manufacturing and control matters; the Company's current clinical trial and any future clinical studies may not produce positive results in a timely fashion, if at all, and could require larger and longer trials, which would be time consuming and costly; plans regarding development, approval and marketing of any of Galectin's drugs are subject to change at any time based on the changing needs of the Company as determined by management and regulatory agencies; regardless of the results of any of its development programs, Galectin may be unsuccessful in developing partnerships with other companies or raising additional capital that would allow it to further develop and/or fund any studies or trials. Galectin has incurred operating losses since inception, and its ability to successfully develop and market drugs may be impacted by its ability to manage costs and finance continuing operations. For a discussion of additional factors impacting Galectin's business, see the Company's Annual Report on Form 10-K for the year ended December 31, 2025, and subsequent filings with the SEC. You should not place undue reliance on forward-looking statements. Although subsequent events may cause its views to change, management disclaims any obligation to update forward-looking statements.
Company Contact:
Jack Callicutt, Chief Financial Officer
(678) 620-3186
...
Investors Relations Contact:
Kevin Gardner
...
Galectin Therapeutics and its associated logo is a registered trademark of Galectin Therapeutics Inc. Belapectin is the USAN assigned name for Galectin Therapeutics' galectin-3 inhibitor belapectin.
Condensed Consolidated Statements of Operations
| | Three Months Ended September 30, | |
| | | |
| | 2026 | | | 2025 | |
| | | | | | |
| Operating expenses: | | | | | | |
| | | | | | |
| Research and development | | $ | 1,564 | | | $ | 2,611 | |
| General and administrative | | | 1,803 | | | | 1,587 | |
| Total operating expenses | | | 3,367 | | | | 4,198 | |
| Total operating loss | | | (3,367 | ) | | | (4,198 | ) |
| Other income (expense): | | | | | | | | |
| Interest income | | | 28 | | | | 39 | |
| Interest expense | | | (786 | ) | | | (1,820 | ) |
| Change in fair value of derivatives | | | 594 | | | | (2,205 | ) |
| Total other income | | | (164 | ) | | | (3,986 | ) |
| | | | | | | | |
| Net loss | | $ | (3,531 | ) | | $ | (8,184 | ) |
| Preferred stock dividends | | | (37 | ) | | | (39 | ) |
| | | | | | | | |
| Net loss applicable to common stock | | $ | (3,568 | ) | | $ | (8,223 | ) |
| | | | | | | | |
| Basic and diluted net loss per share | | $ | (0.04 | ) | | $ | (0.13 | ) |
| Shares used in computing basic and diluted net loss per share | | | 89,621 | | | | 64,205 | |
Condensed Consolidated Balance Sheet Data
| | September 30, 2026 | | | December 31, 2025 | |
| | (in thousands) | |
| Cash and cash equivalents | | $ | 11,706 | | | $ | 17,720 | |
| Total assets | | | 13,009 | | | | 19,532 | |
| Total current liabilities | | | 46,406 | | | | 8,030 | |
| Total liabilities | | | 46,448 | | | | 145,727 | |
| Total redeemable, convertible preferred stock | | | 1,723 | | | | 1,723 | |
| Total stockholders' deficit | | $ | (35,162 | ) | | $ | (127,918 | ) |

Comments
No comment